The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
Baba
T
T
Shimada
K
K
Neugebauer
S
S
Yamada
D
D
Hashimoto
S
S
Watanabe
T
T
D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008222:Lymphokines / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use*; D000077205:Pioglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007004:Hypoglycemic Agents; D008222:Lymphokines; D013844:Thiazoles; D045162:Thiazolidinediones; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D008687:Metformin; D000077205:Pioglitazone